The Great Stem Cell Divide
By Michelle L. Brandt,
Stanford Medicine Magazine
| 09. 30. 2004
The science and politics of stem cell research
Stanford physician Michael Lyons, MD, is not a stem cell researcher. But when the Connecticut House Speaker recently called him to discuss her "cautious, maybe even negative, feelings" about a state bill that would endorse embryonic stem cell research, the Stanford genetics fellow was happy to oblige. The state lawmaker felt uneasy about portions of the bill, so Lyons patiently defined complex scientific terms, clarified the differences between this type of research and reproductive cloning, and outlined what he saw as the merits of the work.
By the end of the conversation he had convinced his mom that she should support the legislation.
Lyons and his mother, Speaker Moira Lyons, are just two of many to dive into the debate surrounding stem cells, undeveloped cells that can be coaxed into growing into any kind of tissue. Stem cells are so small that they can't be seen with the naked eye, yet they tend to cause mass confusion and evoke the largest of responses. In fact, Moira Lyons blames the bill's eventual failure to pass in the Connecticut House on legislators'...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...